OncoMatch/Clinical Trials/NCT06653010
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
Is NCT06653010 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Universal CAR-T cells for crc (colorectal cancer).
Treatment: Universal CAR-T cells — This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: GUCY2C expression ≥1+ in ≥50% of the area by IHC (≥1+ in ≥50% of the area by IHC)
Tumor lesions assessed by immunohistochemistry (IHC) showing GCC expression ≥1+ in ≥50% of the area
Disease stage
Metastatic disease required
Pathologically confirmed metastatic colorectal cancer with radiographically confirmed metastatic lesions (e.g., CT or MRI)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — advanced/metastatic
Participants with advanced colorectal cancer who have progressed or are intolerant after ≥2 lines of standard therapy
Cannot have received: chemotherapy
Received chemotherapy...within 14 days prior to cell collection
Cannot have received: targeted therapy
Received...targeted therapy...within 14 days prior to cell collection
Cannot have received: monoclonal antibody therapy
Received...monoclonal antibody therapy...within 14 days prior to cell collection
Cannot have received: traditional Chinese medicine anti-tumor therapy
Received...traditional Chinese medicine anti-tumor therapy within 14 days prior to cell collection
Lab requirements
Blood counts
absolute neutrophil count ≥1.5 × 10⁹/l; platelet count ≥80 × 10⁹/l; hemoglobin ≥9 g/dl
Kidney function
serum creatinine ≤1.5 mg/dl (132.6 μmol/l) or egfr ≥50 ml/min/1.73 m²
Liver function
total bilirubin ≤1.5 × uln (≤2.0 × uln for gilbert's syndrome); ast and alt ≤5 × uln
Cardiac function
cardiac ejection fraction >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify